With Rare Resolve, X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. We have successfully developed mavorixafor, receiving U.S. approval for XOLREMDI® (mavorixafor) in its first indication. We are currently advancing mavorixafor for additional patient populations as well, and we are currently enrolling participants in a pivotal, global Phase 3 clinical trial (the 4WARD trial) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts and is publicly traded on the Nasdaq Global Market under the symbol: XFOR